Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 60/758,066, filed Jan 10, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,638,126 | Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb In force · High confidence | ZymoGenetics, Inc. | In force | High confidence | ||
| US 8,685,395 | Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| US 8,974,783 | Methods of Treating Pain Using an IL-31RA or Osmr-B Antagonist In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| US 9,334,322 | Methods of Antagonizing Signal Transduction in Spinal Cord Cells Using an IL-31RA or Osmr-B Antagonist In force · Medium confidence | ZymoGenetics, Inc. | In force | Medium confidence | ||
| US 9,631,022 | Method Treating Neuronal Tissue Inflammation Using an IL-31RA Monoclonal Antibody In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| US 9,828,431 | Use of IL-31RA Monoclonal Antibodies for Treating Neuronal Inflammation In force · Low confidence | ZymoGenetics, Inc. | In force | Low confidence | ||
| Application 15/799,445 | Use of IL-31RA Monoclonal Antibodies for Antagonizing Signal Transduction in Dorsal Root Ganglion Cells Abandoned Abandoned Mar 31, 2019 | ZymoGenetics, Inc. | Abandoned | Abandoned Mar 31, 2019 | ||
| Application 16/227,307 | Use of IL-31RA Monoclonal Antibodies for Antagonizing Signal Transduction in Dorsal Root Ganglion Cells Abandoned Abandoned Mar 16, 2020 | ZymoGenetics, Inc | Abandoned | Abandoned Mar 16, 2020 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by ZymoGenetics Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.